Registration
Advertiser Disclosure

Oncology research and precision drug development by Tyra Biosciences

Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
  • Eugene Komchuk
  • Yesterday
Tyra Biosciences tests oral treatment aiming to lower management burden in NMIBC
Tyra Biosciences has initiated the SURF302 study, focusing on an investigational oral therapeutic approach for patients with non-muscle invasive bladder cancer (NMIBC). The company aims to ...
Tyra Biosciences pursues new treatment strategies for urologic cancers
  • Jose Antonio Gastelum
  • 22.07.2026
Tyra Biosciences pursues new treatment strategies for urologic cancers
Tyra Biosciences is intensifying efforts to advance novel treatment approaches for individuals living with urologic cancers, including IR-NMIBC and LG-UTUC. The company announced its intention ...
Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC
  • Andreas Kristo
  • 14.05.2026
Tyra Biosciences begins dosing in Phase 2 trial for dabogratinib in low grade UTUC
Tyra Biosciences has announced the dosing of the first patient in its Phase 2 clinical trial for SURF303, assessing the investigational oral FGFR3-selective inhibitor dabogratinib in low grade ...
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial
  • Oleg Tkachenko
  • 05.05.2026
Tyra Biosciences initiates partnership with KUMedCenter to advance SURF302 bladder cancer trial
Tyra Biosciences has announced a partnership with the University of Kansas Medical Center to support participants in the SURF302 clinical trial, an effort focused on advancing research in bladder ...
Dabo gratinib designation honors key Tyra Biosciences executives
  • Dmytro Kharkov
  • 24.03.2026
Dabo gratinib designation honors key Tyra Biosciences executives
Tyra Biosciences revealed that the name “Dabo” derives from the combination of Daniel Bensen, Co-founder and Chief Discovery Officer, and Robert L. Hudkins, Chief Technology Officer, ...
Tyra Biosciences deepens industry engagement at EAU26 meeting
  • Olesia Kramarenko
  • 14.03.2026
Tyra Biosciences deepens industry engagement at EAU26 meeting
Tyra Biosciences is actively networking with key figures from the urologic oncology community at the EAU26 conference. The company is participating in discussions that are expected to influence ...
ACMG meeting attendance advances FGFR3 inhibition work, Tyra Biosciences outlines
  • Olga Shendetskaya
  • 13.03.2026
ACMG meeting attendance advances FGFR3 inhibition work, Tyra Biosciences outlines
Tyra Biosciences is attending the ACMG 2026 Annual Clinical Genetics Meeting in Baltimore this week. The company is engaging with industry professionals to discuss its latest developments in ...
Tyra Biosciences backs cancer forum to advance urologic oncology
  • Dmytro Kharkov
  • 27.10.2025
Tyra Biosciences backs cancer forum to advance urologic oncology
Tyra Biosciences has announced its support for the Bladder & Kidney Cancer Academy, marking a significant involvement in conversations aimed at addressing unmet needs in non-muscle invasive ...
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org World Association of News Publishers https://gdpr.eu/ GDPR